Example: Heart Attack

Search clinical trials for: Excitatory Amino Acid Antagonists

Total 1576 results

NCT02511873

Unknown status

Fycompa in Subjects With Small Fiber Neuropathy (SFN)

Conditions: Neuropathy, Small Fiber
NCT01507181

Completed

Ketamine For Suicidal Ideation

Conditions: Suicidal Ideation
NCT02967640

Recruiting

Does Subacromial Injection With Glutamate Receptor Antagonist, Ketamine, Attenuate Pain in Rotator Cuff Tendinopathy?

Conditions: Rotator Cuff Tendinitis; Chronic Pain
NCT01018056

Completed

Developing New Treatments for Tourette Syndrome: Therapeutic Trials With Modulators of Glutamatergic Neurotransmission

Conditions: Tourette Syndrome
NCT04101474

Not yet recruiting

Role Of Ketamine in Treatment-Resistant Major Depressive Disorder And Its Effect on Suicidality

Conditions: Treatment Resistant Depression
NCT00001929

Completed

Treatment of Parkinson's Disease With Eliprodil

Conditions: Movement Disorders; Parkinson Disease
NCT02363933

Completed

Perampanel in Seizure Patients With Primary Glial Brain Tumors

Conditions: Brain Tumor, Primary
NCT00001365

Completed

Dextromethorphan for the Treatment of Parkinson's Disease and Similar Conditions of the Nervous System

Conditions: Neurodegenerative Disease; Parkinson's Disease
NCT00001930

Completed

Treatment of Huntington's Chorea With Amantadine

Conditions: Chorea; Huntington's Disease
NCT04032301

Recruiting

Repeated Ketamine Infusions for Comorbid PTSD and MDD in Veterans

Conditions: Post-Traumatic Stress Disorders; Major Depressive Disorder
NCT02577250

Completed

Ketamine Infusions for PTSD and Treatment-Resistant Depression

Conditions: Depressive Disorder, Treatment-Resistant; Stress Disorders, Post-Traumatic
NCT00251303

Completed

Riluzole to Treat Child and Adolescent Obsessive-Compulsive Disorder With or Without Autism Spectrum Disorders

Conditions: Obsessive-Compulsive Disorder; Autism Spectrum Disorder; Autism; Asperger Disorder; Developmental Disorder
NCT03051256

Completed

Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg Daily and 50 mg Daily of REL-1017 in Major Depressive Disorder

Conditions: Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant
NCT01548703

Completed

A Multiple Ascending Dose Study of BCI-838 in Healthy Volunteers

Conditions: Healthy
NCT01546051

Completed

A Study of BCI-838 and Several BCI-632 Prodrugs in Healthy Volunteers

Conditions: Healthy
NCT02340325

Completed

FS2 Safety and Tolerability Study in Healthy Volunteers

Conditions: Cicatrix; Cicatrix, Hypertrophic; Keloid
NCT02634684

Completed

Pharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.

Conditions: Schizophrenia
NCT00108667

Completed

Talampanel to Treat Parkinson's Disease

Conditions: Parkinson Disease
NCT02426983

Unknown status

Pilot Study Using an NMDA Antagonist to Modulate Transcranial Direct Current Stimulation (tDCS) Effects on Sensory Discrimination

Conditions: Schizophrenia
NCT00034229

Completed

Clinical Trial of Felbamate for Treatment-Resistant Bipolar Depression

Conditions: Bipolar Disorder
NCT01553435

Unknown status

Effect of N-methyl D-aspartate (NMDA) Receptor Antagonist Dextromethorphan on Opiods Analgesia and Tolerance in Pediatric Intensive Care Unit Patients

Conditions: Pain; Opioid Tolerance; Analgesia Tolerance
NCT01602185

Completed

Study of NMDA Antagonists and Neuropathic Pain

Conditions: Neuropathic Pain
NCT03336398

Recruiting

Investigation of the NMDA Antagonist Ketamine as a Treatment for Tinnitus

Conditions: Tinnitus
NCT01833897

Completed

NMDA Antagonists in Bipolar Depression

Conditions: Bipolar Disorder
NCT02087202

Unknown status

Hyperalgesia and NMDA Receptor Antagonist

Conditions: Pain